Pop vaccine stocks; BioNTech CEO Says Omicron Reports Need For Annual Shots – .

Pop vaccine stocks; BioNTech CEO Says Omicron Reports Need For Annual Shots – .

Vaccine stocks jumped on Friday after BioNTechThe chief executive of (BNTX) said the emergence of the highly mutated omicron variant signals the need for annual Covid boosters.


The variant appeared last month and carries a number of mutations to its spike protein. These could help him escape the vaccines. Vaccines Modern (MRNA) and BioNTech with its partner Pfizer (PFE) introduce the body into the spike protein to induce an immune response.

BioNTech chief executive Ugur Sahin said omicron could lead to more infections in those vaccinated. Researchers say the variant could be more transmissible, although it’s still not clear whether it will cause more severe cases of respiratory disease.

“This highly mutant virus has arrived earlier than expected,” Sahin said, according to Reuters. “I expected it next year and he’s already with us. “

The earlier than expected emergence of omicron could signal the need for annual vaccinations, he said. BioNTech said it takes two weeks to determine whether omicron will need a new vaccine. The company then needs six weeks to reconfigure its existing plan.

Vaccine stocks: the best booster?

In today’s stock market, stocks of Pfizer and BioNTech vaccines have jumped. Pfizer stock rose 2.3% to 54.27. BioNTech stock jumped 3.2% to 344.06. Moderna stock yo-yoed and ultimately ended the session up 1.7% to 306.72.

Moderna’s decision follows a promising study published in the medical journal The Lancet. The test tracked the safety and effectiveness of various Covid vaccine booster strategies. They included messenger RNA injections from Pfizer-BioNTech and Moderna, as well as other vaccine stock strategies like Johnson & Johnson (JNJ), Novavax (NVAX), AstraZeneca (AZN) et CureVac (CVAC).

SVB Leerink analysts said there was “no definitive winner”. Moderna’s vaccine offers the highest levels of antibodies to stop infections immediately after the booster, they wrote in a report to customers. But with that comes a risk of severe fatigue.

The experimental shot of the Novavax vaccine stock appears to be the most tolerable, but also produces a lower level of enhanced antibodies and cellular immunity, analysts said. The antibodies recognize the spike protein and then destroy it.

Another immune response involves T cells. These immune cells recognize and destroy infected cells. The best option for loading T cells is to follow an initial round of mRNA with a J&J boost. This option gave individuals a good chance against the variants, analysts said.

Overall, “Moderna’s full-dose vaccine is very effective and is a very effective booster, but also has a high rate of local and systemic reactions,” analysts said. “The Pfizer / BioNTech Comirnaty is the ‘decathlete’ with decent antibody and T cell booster responses. “

The FDA will act quickly

Also on Friday, the Wall Street Journal reported that the Food and Drug Administration plans to speed up reviews of vaccines and drugs targeting the omicron variant.

The report quotes people familiar with the matter.

The Moderna vaccine stock has announced its intention to assess four potential candidates against the variant. BioNTech and J&J are still testing to determine if a new injection is needed. Novavax and Inovio Pharmaceuticals (INO) say they are developing vaccine candidates to tackle omicron.

Processing companies like Regeneron Pharmaceuticals (RAIN) et Eli Lilly (LLY) say they are still evaluating the potential impact omicron might have on their antibody-based drugs.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Aurinia Pharma rises again as Novartis joins list of potential suitors

Xenon cancels out early gain and dives despite promising epilepsy results

Looking for the next apple or Amazon? Start With These S&P 500 Win Lists

Find the best growing stocks of the moment to watch with IBD 50

Run custom inventory screens with MarketSmith


Please enter your comment!
Please enter your name here